Annotation Detail

Information
Associated Genes
NTRK2
Associated Variants
NTRK2 ETV6-NTRK2
Associated Disease
acute myeloid leukemia
Source Database
CIViC Evidence
Description
Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. In this manuscript, TRK fusions were screened for in 7,311 patients with a variety of hematologic malignancies. Overall, 8 TRK-fusions were identified including 1 ETV6-NTRK2 fusion in a patient with acute myeloid leukemia (AML) Treatment with TRK-Inhibitor larotrectinib led to a partial Response in an AML patient with ETV6-NTRK2 fusion after sucessful xenograft studies.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/6396
Gene URL
https://civic.genome.wustl.edu/links/genes/3984
Variant URL
https://civic.genome.wustl.edu/links/variants/2396
Rating
4
Evidence Type
Predictive
Disease
Acute Myeloid Leukemia
Evidence Direction
Supports
Drug
Larotrectinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
29920189
Drugs
Drug NameSensitivitySupported
LarotrectinibSensitivitytrue